Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of daytime continuous subcutaneous apomorphine infusion in stable Parkinson's disease patients
2021-000826-89Phase 4Completed
- Sponsor
- CHU Rennes
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by CHU Rennes. Primary endpoint: AUC0-24 of plasma apomorphine concentrations. Started Mar 2021; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2021-000826-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000826-89.